164 related articles for article (PubMed ID: 34638774)
1. Human CD22-Transgenic, Primary Murine Lymphoma Challenges Immunotherapies in Organ-Specific Tumor Microenvironments.
Gsottberger F; Brandl C; Wendland K; Petkovic S; Emmerich C; Erber R; Geppert C; Hartmann A; Mackensen A; Nitschke L; Müller F
Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638774
[TBL] [Abstract][Full Text] [Related]
2. Human CD22 Inhibits Murine B Cell Receptor Activation in a Human CD22 Transgenic Mouse Model.
Bednar KJ; Shanina E; Ballet R; Connors EP; Duan S; Juan J; Arlian BM; Kulis MD; Butcher EC; Fung-Leung WP; Rao TS; Paulson JC; Macauley MS
J Immunol; 2017 Nov; 199(9):3116-3128. PubMed ID: 28972089
[TBL] [Abstract][Full Text] [Related]
3. Glycoengineering of NK Cells with Glycan Ligands of CD22 and Selectins for B-Cell Lymphoma Therapy.
Hong S; Yu C; Wang P; Shi Y; Cao W; Cheng B; Chapla DG; Ma Y; Li J; Rodrigues E; Narimatsu Y; Yates JR; Chen X; Clausen H; Moremen KW; Macauley MS; Paulson JC; Wu P
Angew Chem Int Ed Engl; 2021 Feb; 60(7):3603-3610. PubMed ID: 33314603
[TBL] [Abstract][Full Text] [Related]
4. Establishment of humanized tumor microenvironment mouse models based on the injection of peripheral blood mononuclear cells and IFN-γ to evaluate the efficacy of PD-L1/PD-1-targeted immunotherapy.
Lin X; Zeng T; Lin J; Zhang Q; Cheng H; Fang S; Lin S; Chen Y; Xu Y; Lin J
Cancer Biol Ther; 2020; 21(2):130-138. PubMed ID: 31690181
[TBL] [Abstract][Full Text] [Related]
5. Human CD22 cannot fully substitute murine CD22 functions in vivo, as shown in a new knockin mouse model.
Wöhner M; Born S; Nitschke L
Eur J Immunol; 2012 Nov; 42(11):3009-18. PubMed ID: 22965838
[TBL] [Abstract][Full Text] [Related]
6. Preclinical evaluation of a diabody-based (177)Lu-radioimmunoconjugate for CD22-directed radioimmunotherapy in a non-Hodgkin lymphoma mouse model.
Weber T; Bötticher B; Arndt MA; Mier W; Sauter M; Exner E; Keller A; Krämer S; Leotta K; Wischnjow A; Grosse-Hovest L; Strumberg D; Jäger D; Gröne HJ; Haberkorn U; Brem G; Krauss J
Cancer Lett; 2016 Oct; 381(2):296-304. PubMed ID: 27524505
[TBL] [Abstract][Full Text] [Related]
7. Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and Its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin's lymphoma.
Stein R; Qu Z; Chen S; Rosario A; Shi V; Hayes M; Horak ID; Hansen HJ; Goldenberg DM
Clin Cancer Res; 2004 Apr; 10(8):2868-78. PubMed ID: 15102696
[TBL] [Abstract][Full Text] [Related]
8. Efficient elimination of primary B-ALL cells in vitro and in vivo using a novel 4-1BB-based CAR targeting a membrane-distal CD22 epitope.
Velasco-Hernandez T; Zanetti SR; Roca-Ho H; Gutierrez-Aguera F; Petazzi P; Sánchez-Martínez D; Molina O; Baroni ML; Fuster JL; Ballerini P; Bueno C; Fernandez-Fuentes N; Engel P; Menendez P
J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32788237
[TBL] [Abstract][Full Text] [Related]
9. Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia.
Haso W; Lee DW; Shah NN; Stetler-Stevenson M; Yuan CM; Pastan IH; Dimitrov DS; Morgan RA; FitzGerald DJ; Barrett DM; Wayne AS; Mackall CL; Orentas RJ
Blood; 2013 Feb; 121(7):1165-74. PubMed ID: 23243285
[TBL] [Abstract][Full Text] [Related]
10. Anti-CD22 immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-positive hematologic malignancies of childhood: preclinical studies and phase I clinical trial.
Wayne AS; Kreitman RJ; Findley HW; Lew G; Delbrook C; Steinberg SM; Stetler-Stevenson M; Fitzgerald DJ; Pastan I
Clin Cancer Res; 2010 Mar; 16(6):1894-903. PubMed ID: 20215554
[TBL] [Abstract][Full Text] [Related]
11. Splicing-Mediated Antigen Escape from Immunotherapy for B-cell Malignancies.
Bourcier J; Abdel-Wahab O
Blood Cancer Discov; 2022 Mar; 3(2):87-89. PubMed ID: 35015686
[TBL] [Abstract][Full Text] [Related]
12. High treatment efficacy by dual targeting of Burkitt's lymphoma xenografted mice with a (177)Lu-based CD22-specific radioimmunoconjugate and rituximab.
Weber T; Bötticher B; Mier W; Sauter M; Krämer S; Leotta K; Keller A; Schlegelmilch A; Grosse-Hovest L; Jäger D; Haberkorn U; Arndt MA; Krauss J
Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):489-98. PubMed ID: 26341366
[TBL] [Abstract][Full Text] [Related]
13. Characterization of the anti-CD22 targeted therapy, moxetumomab pasudotox, for B-cell precursor acute lymphoblastic leukemia.
Kinjyo I; Matlawska-Wasowska K; Chen X; Monks NR; Burke P; Winter SS; Wilson BS
Pediatr Blood Cancer; 2017 Nov; 64(11):. PubMed ID: 28449314
[TBL] [Abstract][Full Text] [Related]
14. The antitumor activity of an anti-CD22 immunotoxin in SCID mice with disseminated Daudi lymphoma is enhanced by either an anti-CD19 antibody or an anti-CD19 immunotoxin.
Ghetie MA; Tucker K; Richardson J; Uhr JW; Vitetta ES
Blood; 1992 Nov; 80(9):2315-20. PubMed ID: 1384801
[TBL] [Abstract][Full Text] [Related]
15. Two Saporin-Containing Immunotoxins Specific for CD20 and CD22 Show Different Behavior in Killing Lymphoma Cells.
Polito L; Mercatelli D; Bortolotti M; Maiello S; Djemil A; Battelli MG; Bolognesi A
Toxins (Basel); 2017 May; 9(6):. PubMed ID: 28556822
[TBL] [Abstract][Full Text] [Related]
16. Organization of the murine Cd22 locus. Mapping to chromosome 7 and characterization of two alleles.
Law CL; Torres RM; Sundberg HA; Parkhouse RM; Brannan CI; Copeland NG; Jenkins NA; Clark EA
J Immunol; 1993 Jul; 151(1):175-87. PubMed ID: 8100843
[TBL] [Abstract][Full Text] [Related]
17. Effects of specific anti-B and/or anti-plasma cell immunotherapy on antibody production in baboons: depletion of CD20- and CD22-positive B cells does not result in significantly decreased production of anti-alphaGal antibody.
Alwayn IP; Xu Y; Basker M; Wu C; Buhler L; Lambrigts D; Treter S; Harper D; Kitamura H; Vitetta ES; Abraham S; Awwad M; White-Scharf ME; Sachs DH; Thall A; Cooper DK
Xenotransplantation; 2001 Aug; 8(3):157-71. PubMed ID: 11472623
[TBL] [Abstract][Full Text] [Related]
18. CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy.
Fry TJ; Shah NN; Orentas RJ; Stetler-Stevenson M; Yuan CM; Ramakrishna S; Wolters P; Martin S; Delbrook C; Yates B; Shalabi H; Fountaine TJ; Shern JF; Majzner RG; Stroncek DF; Sabatino M; Feng Y; Dimitrov DS; Zhang L; Nguyen S; Qin H; Dropulic B; Lee DW; Mackall CL
Nat Med; 2018 Jan; 24(1):20-28. PubMed ID: 29155426
[TBL] [Abstract][Full Text] [Related]
19. Genetically engineered macrophages persist in solid tumors and locally deliver therapeutic proteins to activate immune responses.
Brempelis KJ; Cowan CM; Kreuser SA; Labadie KP; Prieskorn BM; Lieberman NAP; Ene CI; Moyes KW; Chinn H; DeGolier KR; Matsumoto LR; Daniel SK; Yokoyama JK; Davis AD; Hoglund VJ; Smythe KS; Balcaitis SD; Jensen MC; Ellenbogen RG; Campbell JS; Pierce RH; Holland EC; Pillarisetty VG; Crane CA
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33115946
[TBL] [Abstract][Full Text] [Related]
20. [Immune-checkpoint and hemopathies].
Burroni B; Broudin C; Damotte D; Laurent C
Ann Pathol; 2017 Feb; 37(1):101-110. PubMed ID: 28161001
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
